about
Role of DNA repair machinery and p53 in the testicular germ cell cancer: a reviewCarcinogenetic mechanisms of endocrine disruptors in female cancers (Review)Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen.Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancerFrom Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall SurvivalPazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale"Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implicationsRectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.Peg-filgrastim and cabazitaxel in prostate cancer patients.Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests.Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?Nomegestrol acetate/estradiol hormonal oral contraceptive and breast cancer risk.Endocrine disruptors and female cancer: Informing the patients (Review).Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma.Serum and tissue markers in colorectal cancer: State of art.Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results.Current and Emerging Treatments for Metastatic Renal Cell Carcinoma.MELANOMA ADJUVANT TREATMENT: current insight and clinical features.Study on the use of focus harmonic scalpel in thyroidectomies: is it useful also in preserving voice function?In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches.Corrigendum: Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale"Corrigendum: Prevalence of increases in functional connectivity in visual, somatosensory and language areas in congenital blindness.Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.Optimal Management of Prostate Cancer Based on its Natural Clinical History.Letter to the Editor - miR-494 inhibits invasion and proliferation of gastric cancer by targeting IGF-1R.A banking strategy toward customized therapy in breast cancerClinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and youngerLetter to the Editor - Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment
P50
Q28069963-07ED064C-3E01-4F6D-8372-0C4204E19CFFQ28596765-6748D68E-00A2-4297-A4C5-729681A43C6EQ35743480-8887BFC3-5C86-4709-8B8D-4C002F102401Q36728989-EC695123-EA0C-48D8-A3A2-6443C49A5E0DQ36859124-8C80B794-7AA6-44C1-B713-012FABAA4628Q36909750-09EB95F5-270F-4975-BF90-5A16AAA2AD0EQ37218304-FA48BB9C-4568-43C1-95B4-C32466A2B0AFQ37290050-0DB8229F-B696-4713-B3E4-C6E69CF1A938Q37706763-5D26315D-B4AB-44A0-BDD1-F65EE193C3AEQ37725623-023D0EFA-3EFE-4649-9349-D20C2139EDA9Q38050328-3FDDD6FB-E6FA-4A43-8334-16F3C7980DDAQ38136422-01CCF4E4-46A5-44E7-9569-C264CBFD0512Q38147864-3D0C2A43-7F61-45BF-80AB-E5E8DE50E541Q38171959-54D705ED-5342-410A-8B65-498546CFD042Q38495995-3FD6C67A-223C-4FF3-B2E8-0F13752E06EDQ38560628-B17B541D-28E6-466D-8671-5908E3966BC9Q38642100-5F3C4F52-4F02-4638-B9C9-E97FB4AD149AQ38750780-32927FB4-77F6-4944-8654-90CB791512D8Q38825993-0B6D2E30-A749-41D0-8A5C-D567B44DCDB7Q38969207-9C51737E-A907-4CB8-9CB4-BB18FF4E87F9Q38969212-3771BB3A-86CD-48CE-89D2-C325F0A63308Q39370153-3810C45C-D17A-4C90-AF93-E2CD90373370Q40033905-E7CFE9E0-3E7E-4204-9E74-E2989B091DB8Q42359052-659D74EA-A671-4D6A-8716-002668499E6EQ42495120-5DF85277-4812-4DBB-A4E4-0DD7D85AC570Q51052339-0B67D3E7-A5A1-4356-AC0B-F8D70380C6E6Q52792458-3EB80356-C351-4E16-ADD6-2D842E6740D6Q54161744-440FAA78-8063-4F13-87D6-385B9BFCEA13Q83275347-7C556B40-37D9-4DB9-B2CA-7BDAF9CFAA38Q87176751-57EDCBE3-131A-428B-A1DF-E97C1C20F708Q95369748-E69F0DC5-3EE4-44E8-86A3-F8C51156CE9C
P50
description
researcher ORCID ID = 0000-0002-2048-7819
@en
wetenschapper
@nl
name
Carla Cavaliere
@ast
Carla Cavaliere
@en
Carla Cavaliere
@es
Carla Cavaliere
@nl
type
label
Carla Cavaliere
@ast
Carla Cavaliere
@en
Carla Cavaliere
@es
Carla Cavaliere
@nl
prefLabel
Carla Cavaliere
@ast
Carla Cavaliere
@en
Carla Cavaliere
@es
Carla Cavaliere
@nl
P106
P1153
35483429200
P21
P31
P496
0000-0002-2048-7819